Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Hold” by Brokerages

Posted by Francis Steltz on Jul 29th, 2026

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) has received a consensus rating of “Hold” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $6.75.

A number of equities research analysts recently issued reports on the company. Mizuho assumed coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Guggenheim upped their price objective on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, April 10th. Finally, Rodman & Renshaw assumed coverage on Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price objective on the stock.

Read Our Latest Research Report on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Trading Up 2.4%

NASDAQ:ZNTL opened at $4.62 on Wednesday. The company has a market capitalization of $328.90 million, a P/E ratio of -2.67 and a beta of 1.92. The firm has a 50-day moving average price of $4.19 and a two-hundred day moving average price of $3.52. Zentalis Pharmaceuticals has a twelve month low of $1.21 and a twelve month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). On average, equities research analysts predict that Zentalis Pharmaceuticals will post -1.83 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 177.6% during the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after buying an additional 396,233 shares in the last quarter. Millennium Management LLC raised its position in shares of Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after buying an additional 2,111,951 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $37,000. Sei Investments Co. lifted its stake in shares of Zentalis Pharmaceuticals by 373.1% during the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock valued at $194,000 after buying an additional 131,780 shares during the period. Finally, Jane Street Group LLC boosted its position in Zentalis Pharmaceuticals by 346.3% during the second quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock worth $770,000 after acquiring an additional 515,257 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

(Get Free Report)

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.